Simon Read - 22 May 2025 Form 4 Insider Report for Dianthus Therapeutics, Inc. /DE/ (DNTH)

Role
Director
Signature
/s/ Adam Veness, as attorney-in-fact for Simon Read
Issuer symbol
DNTH
Transactions as of
22 May 2025
Net transactions value
$0
Form type
4
Filing time
22 May 2025, 16:40:11 UTC
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Read Simon Director C/O DIANTHUS THERAPEUTICS, INC., 7 TIMES SQUARE, 43RD FLOOR, NEW YORK /s/ Adam Veness, as attorney-in-fact for Simon Read 22 May 2025 0001688199

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction DNTH Stock Option (Right to Buy) Award $0 +25,000 $0.000000 25,000 22 May 2025 Common Stock 25,000 $18.36 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares of common stock underlying this stock option award will vest as to one-third of the shares subject to the option on each of the first, second and third anniversaries of the date of grant, subject to the Reporting Person's continued service to the Issuer on each such vesting date.